Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Kohn Website

Elise C. Kohn, M.D.

Selected Publications
1)  Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer. 119: 1357-64, 2013. [Journal]
2)  Kohn EC, Hurteau J.
Ovarian cancer : making its own rules-again.
Cancer. 119: 474-6, 2013. [Journal]
3)  Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC.
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Mol. Cell Proteomics. [Epub ahead of print], 2013. [Journal]
4)  Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC.
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.
Cancer. 118: 1543-53, 2012. [Journal]
5)  Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R, Kohn EC.
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.
Angiogenesis. 15: 33-45, 2012. [Journal]
6)  Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, Virador V, Kohn EC.
L-Asparaginase Inhibits Invasive And Angiogenic Activity And Induces Autophagy In Ovarian Cancer.
J Cell Mol Med. 16: 2369-78, 2012. [Journal]
7)  Annunziata CM, Kohn EC, Lorusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R.
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
Invest New Drugs. [Epub ahead of print], 2012. [Journal]
8)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012. [Journal]
9)  Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H.
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study.
Gynecol. Oncol. 122: 89-94, 2011. [Journal]
10)  Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, Stassi G, Marfia A, Iovino F, Arlinghaus R, Kohn EC, Leo GD, Alessandro R.
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Cancer Lett. 300: 205-14, 2011. [Journal]
11)  Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, Kolli VS, Kirchner D, Litzi T, Maxwell GL.
Identifier mapping performance for integrating transcriptomics and proteomics experimental results.
BMC Bioinformatics. 12: 213, 2011. [Journal]
12)  Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S, Davidson B, Kohn EC.
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.
Gynecol. Oncol. 122: 656-62, 2011. [Journal]
13)  Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Br J Clin Pharmacol. 72: 294-305, 2011. [Journal]
14)  Han JJ, Yu M, Houston N, Steinberg SM, Kohn EC.
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.
Gynecol. Oncol. 120: 5-10, 2011. [Journal]
15)  Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, Bateman NW, Allard J, Miller C, Sun M, Flint MS, Zahn C, Oliver J, Banerjee S, Litzi T, Parwani A, Sandburg G, Rose S, Becich MJ, Berchuck A, Kohn E, Risinger JI, Conrads TP.
Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.
Gynecol. Oncol. 121: 586-94, 2011. [Journal]
16)  Lee J, Han JJ, Altwerger G, Kohn EC.
Proteomics and biomarkers in clinical trials for drug development.
J Proteomics. 74: 2632-41, 2011. [Journal]
17)  Taverna S, Flugy A, Saieva L, Kohn EC, Santoro A, Meraviglia S, De Leo G, Alessandro R.
Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis.
Int J Cancer. 130: 2033-43, 2011. [Journal]
18)  Morrison C, Miecznikowski J, Darcy KM, Dolce JM, Kandel E, Erwin DO, Liu S, Shepherd L, Cohn D, McMeekin DS, Block AW, Nowak NJ, Maxwell L.
A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome.
Genes Chromosomes Cancer. 49: 791-802, 2010. [Journal]
19)  Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM.
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
Cancer Res. 70: 4005-14, 2010. [Journal]
20)  McCollum AK, Casagrande G, Kohn EC.
Caught in the middle: the role of Bag3 in disease.
Biochem. J. 425: e1-3, 2010. [Journal]
21)  Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, Thigpen JT, Fleming GF, Gallion HH, Maxwell GL.
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.
Cancer. 116: 355-61, 2010. [Journal]
22)  Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC.
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Br. J. Cancer. 102: 495-9, 2010. [Journal]
23)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010. [Journal]
24)  Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC.
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.
Cancer. 116: 3276-84, 2010. [Journal]
25)  Hays JL, Kim G, Giuroiu I, Kohn EC.
Proteomics and ovarian cancer: Integrating proteomics information into clinical care.
Journal of proteomics. 2010. [Journal]
26)  Lee JM, Kohn EC.
Proteomics as a guiding tool for more effective personalized therapy.
Ann. Oncol. 21 Suppl 7: vii205-vii210, 2010. [Journal]
27)  Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC.
Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.
Clin. Cancer Res. 16: 600-9, 2010. [Journal]
28)  He Y, Blackford JA, Kohn EC, Simons SS.
STAMP alters the growth of transformed and ovarian cancer cells.
BMC Cancer. 10: 128, 2010. [Journal]
29)  Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC.
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
Cancer. 116: 1476-84, 2010. [Journal]
30)  Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC.
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Clin. Cancer Res. 16: 664-72, 2010. [Journal]
31)  Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL.
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.
Gynecol. Oncol. 115: 81-5, 2009. [Journal]
32)  Azad N, Perroy A, Gardner E, Imamura CK, Graves C, Sarosy GA, Minasian L, Kotz H, Raggio M, Figg WD, Kohn EC.
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Cancer Biol. Ther. 8: 1800-5, 2009. [Journal]
33)  Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.
Biological significance of prolactin in gynecologic cancers.
Cancer Res. 69: 5226-33, 2009. [Journal]
34)  Zhu K, Devesa SS, Wu H, Zahm SH, Jatoi I, Anderson WF, Peoples GE, Maxwell LG, Granger E, Potter JF, McGlynn KA.
Cancer incidence in the U.S. military population: comparison with rates from the SEER program.
Cancer Epidemiol. Biomarkers Prev. 18: 1740-5, 2009. [Journal]
35)  Elmasri WM, Casagrande G, Hoskins E, Kimm D, Kohn EC.
Cell adhesion in ovarian cancer.
Cancer Treat. Res. 149: 297-318, 2009. [Journal]
36)  Havrilesky LJ, Maxwell GL, Chan JK, Myers ER.
Cost effectiveness of a test to detect metastases for endometrial cancer.
Gynecol. Oncol. 112: 526-30, 2009. [Journal]
37)  Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B.
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
Int. J. Gynecol. Pathol. 28: 211-21, 2009. [Journal]
38)  Kassis JN, Virador VM, Guancial EA, Kimm D, Ho AS, Mishra M, Chuang EY, Cook J, Gius D, Kohn EC.
Genomic and phenotypic analysis reveals a key role for CCN1 (CYR61) in BAG3-modulated adhesion and invasion.
J. Pathol. 2009. [Journal]
39)  Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH.
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clin. Cancer Res. 15: 1411-6, 2009. [Journal]
40)  Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC.
Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.
Cancer Sci. 100: 434-40, 2009. [Journal]
41)  Kim G, Minig L, Kohn EC.
Proteomic profiling in ovarian cancer.
Int. J. Gynecol. Cancer. 19 Suppl 2: S2-6, 2009. [Journal]
42)  Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL.
Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.
Cancer. 115: 4210-7, 2009. [Journal]
43)  von Rosenvinge EC, Gopal LD, Heller T, Kohn EC, Yao MD.
Rectal fistulae resulting from treatment with sorafenib and bevacizumab.
Gastrointest. Endosc. 2009. [Journal]
44)  Virador VM, Davidson B, Czechowicz J, Mai A, Kassis J, Kohn EC.
The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome.
PLoS ONE. 4: e5136, 2009. [Journal]
45)  Kamrava M, Gius D, Casagrande G, Kohn E.
Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective.
Ageing Res. Rev. 2009. [Journal]
46)  Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC, Goldsmith PK, Birrer MJ, Weinstein JN.
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.
Mol. Cancer Ther. 7: 3123-8, 2008. [Journal]
47)  Schrohl AS, Würtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FC, Brünner N.
Banking of biological fluids for studies of disease-associated protein biomarkers.
Mol. Cell Proteomics. 7: 2061-6, 2008. [Journal]
48)  Nguyen P, Bar-Sela G, Sun L, Bisht KS, Cui H, Kohn E, Feinberg AP, Gius D.
BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.
Mol. Cell. Biol. 28: 6720-9, 2008. [Journal]
49)  Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J. Clin. Oncol. 26: 3709-14, 2008. [Journal]
50)  Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, Flugy AM, Santoro A, Kohn EC, De Leo G.
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
J. Cell. Physiol. 215: 111-21, 2008. [Journal]
51)  Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC.
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Cancer. 112: 1726-32, 2008. [Journal]
52)  Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC.
Ovarian cancer in the proteomics era.
Int. J. Gynecol. Cancer. 18 Suppl 1: 1-6, 2008. [Journal]
53)  Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC, Pommier Y.
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
Mol. Cancer Ther. 7: 10-8, 2008. [Journal]
54)  Maxwell GL, Tian C, Risinger JI, Hamilton CA, Barakat RR.
Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?.
Cancer. 113: 1431-7, 2008. [Journal]
55)  Coleman RL, Kohn EC.
Rationale for combination use of targeted agents in ovarian cancer: Do we have one?.
Cancer. 113(4): 665-667, 2008. [Journal]
56)  Yang JL, Qu XJ, Yu Y, Kohn EC, Friedlander ML.
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Int. J. Cancer. 123: 258-63, 2008. [Journal]
57)  Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, Kohn EC.
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
Carcinogenesis. 29: 466-72, 2008. [Journal]
58)  Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC.
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Cancer. 109: 1323-30, 2007. [Journal]
59)  Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC.
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
Cancer. 110: 309-17, 2007. [Journal]
60)  Annunziata CM, Kleinberg L, Davidson B, Berner A, Gius D, Tchabo N, Steinberg SM, Kohn EC.
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.
Clin. Cancer Res. 13: 6585-92, 2007. [Journal]
61)  Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G.
Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines.
J. Proteome Res. 6: 4330-42, 2007. [Journal]
62)  Winters M, Dabir B, Yu M, Kohn EC.
Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays.
Proteomics. 7: 4066-8, 2007. [Journal]
63)  Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G.
Proteomics as a tool for biomarker discovery.
Dis. Markers. 23: 411-7, 2007. [Journal]
64)  Gunn AJ, Hama Y, Koyama Y, Kohn EC, Choyke PL, Kobayashi H.
Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore.
Cancer Sci. 98: 1727-33, 2007. [Journal]
65)  Dhamoon AS, Kohn EC, Azad NS.
The ongoing evolution of proteomics in malignancy.
Drug Discov. Today. 12: 700-8, 2007. [Journal]
66)  Kohn E.
Kufe DW, Pollock R, Weicheselbaum R, Bast R, Gansler C, Holland JF, Frei E, eds.
Invasion and Metastasis. In: Cancer Medicine 7.
Hamilton and London: B. C. Decker; 2006. p. 148-156 [Book Chapter]
67)  Annunziata C, Roque DM, Azad N, Kohn E.
Daoud S, eds.
Application of werum and tissue proteomics to understand and detect solid tumors. In: Proteomics in Cancer Therapy.
Totowa, NJ: Humana Press; 2006. p. in press [Book Chapter]
68)  Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND.
10th Biennial Helene Harris Memorial Trust meeting.
Cancer Res. 66: 2904-6, 2006. [Journal]
69)  Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Mol. Cancer Ther. 5: 2613-23, 2006. [Journal]
70)  Kassis JN, Guancial EA, Doong H, Virador V, Kohn EC.
CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins.
Exp. Cell Res. 312: 2962-71, 2006. [Journal]
71)  Kassis JN, Guancial EA, Doong H, Virador V, Kohn EC.
CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins.
Exp. Cell Res. 312: 2962-71, 2006. [Journal]
72)  Alessandro R, Di Bella MA, Flugy AM, Fontana S, Damiani F, Corrado C, Colomba P, Todaro M, Russo D, Santoro A, Kohn EC, De Leo G.
Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasis.
Virchows Arch. 449: 48-61, 2006. [Journal]
73)  Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer Biol. Ther. 5: 22-7, 2006. [Journal]
74)  Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS.
Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium.
Int. J. Gynecol. Cancer. 16: 463-9, 2006. [Journal]
75)  Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC.
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Clin. Cancer Res. 12: 791-9, 2006. [Journal]
76)  Alessandro R, Fontana S, Kohn E, De Leo G.
Proteomic strategies and their application in cancer research.
Tumori. 91: 447-55, 2006. [Journal]
77)  Azad NS, Rasool N, Annunziata CM, Minasian L, Whitely G, Kohn EC.
Proteomics in clinical trials and practice: present uses and future promise.
Mol Cell Proteomics. 5(10): 1819-1829, 2006. [Journal]
78)  Simpkins F, Espina V, Posadas E, Petricoin EF, Liotta L, Kohn EC.
Protein arrays for clinical proteomics and signal transduction profiling. In: Proteomics in Cancer Research.
Wiley; 2005. In Press. [Book Chapter]
79)  Tchabo N, Guancial E, Czechowicz J, Kohn E.
The role of proteomics in the diagnosis and treatment of ovarian cancer.
Women's Health. 2005. In Press. [Journal]
80)  Tchabo NE, Liel MS, Kohn EC.
Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
Am J Pharmacogenomics. 5: 141-8, 2005. [Journal]
81)  Perabo FG, Demant AW, Wirger A, Schmidt DH, Sitia M, Wardelmann E, Müller SC, Kohn EC.
Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model.
Anticancer Res. 25: 725-9, 2005. [Journal]
82)  Hoffmann S, He S, Jin ML, Masiero L, Wiedemann P, Ryan SJ, Kohn EC.
Carboxyamido-triazole modulates retinal pigment epithelial and choroidal endothelial cell attachment, migration, proliferation, and MMP-2 secretion of choroidal endothelial cells.
Curr Eye Res. 30: 103-13, 2005. [Journal]
83)  Cruysberg LP, Franklin AJ, Sanders J, Self C, Yuan P, Csaky KG, Robinson MR, Kohn EC, Edelhauser HF.
Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2).
Retina (Philadelphia, Pa.). 25: 1022-31, 2005. [Journal]
84)  Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B.
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
Cancer. 103: 2313-9, 2005. [Journal]
85)  Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn EC.
Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer.
Oncogene. 2005. [Journal]
86)  Kohn EC, Travers LA, Kassis J, Broome U, Klominek J.
Malignant effusions are sources of fibronectin and other promigratory and proinvasive components.
Diagn. Cytopathol. 33: 300-8, 2005. [Journal]
87)  Boyce EA, Kohn EC.
Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Int. J. Gynecol. Cancer. 15 Suppl 3: 266-73, 2005. [Journal]
88)  Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC.
Proteomic analysis for the early detection and rational treatment of cancer--realistic hope?.
Ann Oncol. 16: 16-22, 2005. [Journal]
89)  Alessandro R, Belluco C, Kohn EC.
Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery.
Clin Colorectal Cancer. 4: 396-402, 2005. [Journal]
90)  Alessandro R, Kohn EC, Fontana S, De Leo G.
Proteomic strategies and their application in cancer research.
Tumori. 91: 447-455, 2005. [Journal]
91)  Simpkins F, Czechowicz JA, Liotta L, Kohn EC.
SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.
Pharmacogenomics. 6: 647-53, 2005. [Journal]
92)  Winters ME, Mehta AI, Petricoin EF, Kohn EC, Liotta LA.
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Cancer Res. 65: 3853-60, 2005. [Journal]
93)  Tchabo NE, Guancial EA, Czechowicz JA, Kohn EC.
The role of proteomics in the diagnosis and treatment of ovarian cancer.
Womens Health (Lond Engl). 1: 365-74, 2005. [Journal]
94)  Kassis J, Klominek J, Kohn EC.
Tumor microenvironment: what can effusions teach us?.
Diagn. Cytopathol. 33: 316-9, 2005. [Journal]
95)  Miller WJ, Kayton ML, Patton A, O'Connor S, He M, Vu H, Baibakov G, Lorang D, Knezevic V, Kohn E, Alexander HR, Stirling D, Payvandi F, Muller GW, Libutti SK.
A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay.
J Transl Med. 2: 4, 2004. [Journal]
96)  Liotta LA, Kohn E.
Anoikis: cancer and the homeless cell.
Nature. 430: 973-4, 2004. [Journal]
97)  Franklin AJ, Jetton TL, Kuchemann CL, Russell SR, Kohn EC.
CAI is a potent inhibitor of neovascularization and imparts neuroprotection in a mouse model of ischemic retinopathy.
Invest Ophthalmol Vis Sci. 45: 3756-66, 2004. [Journal]
98)  Perabo FG, Wirger A, Kamp S, Lindner H, Schmidt DH, Müller SC, Kohn EC.
Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2.
Anticancer Res. 24: 2869-77, 2004. [Journal]
99)  Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC.
Granulin-epithelin precursor (GEP) is a novel progostsic marker in epithelial ovarian cancer.
CANCER. in press, 2004. [Journal]
100)  Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC.
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Cancer. 100: 2139-47, 2004. [Journal]
101)  Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G, Barrett JC, Liotta LA, Petricoin EF, Veenstra TD.
High-resolution serum proteomic features for ovarian cancer detection.
Endocr Relat Cancer. 11: 163-78, 2004. [Journal]
102)  Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB.
Molecular therapeutics: promise and challenges.
Semin Oncol. 31: 39-53, 2004. [Journal]
103)  Posadas EM, Davidson B, Kohn EC.
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
Curr Opin Oncol. 16: 478-84, 2004. [Journal]
104)  Stevens EV, Posadas EM, Davidson B, Kohn EC.
Proteomics in cancer.
Ann Oncol. 15 Suppl 4: iv167-71, 2004. [Journal]
105)  Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ.
Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.
Hum Pathol. 35: 934-48, 2004. [Journal]
106)  Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC.
A phase II trial of carboxyamido-triazole (CAI) in patients with relapsed epithelial ovarian cancer.
JOURNAL OF CLINICAL ONCOLOGY. 21: 4356-63, 2003. [Journal]
107)  Romano MF, Festa M, Petrella A, Rosati A, Pascale M, Bisogni R, Poggi V, Kohn EC, Venuta S, Turco MC, Leone A.
BAG3 protein regulates cell survival in childhood acute lymphoblastic leukemia cells.
Cancer Biology and Therapy. 2: 508-510, 2003. [Journal]
108)  Moody TW, Chiles J, Moody E, Sieczkiewicz GJ, Kohn EC.
CAI inhibits the growth of small cell lung cancer cells.
Lung Cancer. 39: 279-88, 2003. [Journal]
109)  Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC.
CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins.
J Biol Chem. 278: 28490-500, 2003. [Journal]
110)  Patton AM, Kassis J, Doong H, Kohn EC.
Calcium as a molecular target in angiogenesis.
Curr Pharm Des. 9: 543-51, 2003. [Journal]
111)  Liotta LA, Kohn EC.
Cancer's deadly signature.
Nat Genet. 33: 10-1, 2003. [Journal]
112)  Liotta LA, Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC.
General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer.
Gynecol Oncol. 88: S25-8; discussion S37-42, 2003. [Journal]
113)  Annunziata CM, Kohn EC.
Is there a genomic basis for primary chemoresistance in ovarian cancer?.
Gynecol Oncol. 90: 1-2, 2003. [Journal]
114)  Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G.
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Semin. Oncol. 30: 93-104, 2003. [Journal]
115)  Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF.
Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer.
Proteomics. 3: 1801-10, 2003. [Journal]
116)  Kohn EC, Mills GB, Liotta L.
Promising directions for the diagnosis and management of gynecological cancers.
Int J Gynaecol Obstet. 83 Suppl 1: 203-9, 2003. [Journal]
117)  Stevens EV, Liotta LA, Kohn EC.
Proteomic analysis for early detection of ovarian cancer: a realistic approach?.
Int. J. Gynecol. Cancer. 13 Suppl 2: 133-9, 2003. [Journal]
118)  Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC.
Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
J Cell Physiol. 197: 139-48, 2003. [Journal]
119)  D'Amato M, Flugy AM, Alaimo G, Bauder B, Kohn EC, De Leo G, Alessandro R.
Role of calcium in E-selectin induced phenotype of T84 colon carcinoma cells.
Biochem Biophys Res Commun. 301: 907-14, 2003. [Journal]
120)  Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J.
Specific keynote: molecular therapeutics in ovarian cancer.
Gynecol Oncol. 88: S88-92; discussion S93-6, 2003. [Journal]
121)  Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, Kohn EC.
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.
Clin Cancer Res. 9: 44-51, 2003. [Journal]
122)  Jones MB, Spooner M, Kohn EC.
The granulin-epithelin precursor: a putative new growth factor for ovarian cancer.
Gynecol Oncol. 88: S136-9, 2003. [Journal]
123)  Sieczkiewicz GJ, Hussain M, Kohn EC.
Angiogenesis and metastasis.
Cancer Treat. Res. 107: 353-81, 2002. [Journal]
124)  Grove AD, Prabhu VV, Young BL, Lee FC, Kulpa V, Munson PJ, Kohn EC.
Both protein activation and gene expression are involved in early vascular tube formation in vitro.
Clin Cancer Res. 8: 3019-26, 2002. [Journal]
125)  Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA.
Clinical proteomics: translating benchside promise into bedside reality.
Nat Rev Drug Discov. 1: 683-95, 2002. [Journal]
126)  Flugy AM, D'Amato M, Russo D, Di Bella MA, Alaimo G, Kohn EC, De Leo G, Alessandro R.
E-selectin modulates the malignant properties of T84 colon carcinoma cells.
Biochem Biophys Res Commun. 293: 1099-106, 2002. [Journal]
127)  Michener CM, Ardekani AM, Petricoin EF, Liotta LA, Kohn EC.
Genomics and proteomics: application of novel technology to early detection and prevention of cancer.
Cancer Detect Prev. 26: 249-55, 2002. [Journal]
128)  Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK.
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
Biotechniques. 33: 664-6, 668, 670, 2002. [Journal]
129)  Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF.
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Proteomics. 2: 76-84, 2002. [Journal]
130)  Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA.
Serum proteomic patterns for detection of prostate cancer.
J Natl Cancer Inst. 94: 1576-8, 2002. [Journal]
131)  Alessandro R, Kohn EC.
Signal transduction targets in invasion.
Clin Exp Metastasis. 19: 265-73, 2002. [Journal]
132)  Liotta LA, Kohn EC.
Stromal therapy: the next step in ovarian cancer treatment.
J Natl Cancer Inst. 94: 1113-4, 2002. [Journal]
133)  Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA.
Use of proteomic patterns in serum to identify ovarian cancer.
Lancet. 359: 572-7, 2002. [Journal]
134)  Doong H, Vrailas A, Kohn EC.
What's in the 'BAG'?--A functional domain analysis of the BAG-family proteins.
Cancer Lett. 188: 25-32, 2002. [Journal]
135)  Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA.
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Clin Cancer Res. 7: 1600-9, 2001. [Journal]
136)  Perabo FG, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, Wirger A, Pegelow K, Albers P, Kohn EC, von Ruecker A, Mueller SC.
Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.
Br J Cancer. 84: 1330-8, 2001. [Journal]
137)  Liotta LA, Kohn EC, Petricoin EF.
Clinical proteomics: personalized molecular medicine.
JAMA. 286: 2211-4, 2001. [Journal]
138)  Mills GB, Lu Y, Kohn EC.
Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.
Proc Natl Acad Sci U S A. 98: 10031-3, 2001. [Journal]
139)  Lapidos KA, Woodhouse EC, Kohn EC, Masiero L.
Mg(++)-induced endothelial cell migration: substratum selectivity and receptor-involvement.
Angiogenesis. 4: 21-8, 2001. [Journal]
140)  Liotta LA, Kohn EC.
The microenvironment of the tumour-host interface.
Nature. 411: 375-9, 2001. [Journal]
141)  Brown MR, Blanchette JO, Kohn EC.
Angiogenesis in ovarian cancer.
Baillieres Best Pract Res Clin Obstet Gynaecol. 14: 901-18, 2000. [Journal]
142)  Doong H, Price J, Kim YS, Gasbarre C, Probst J, Liotta LA, Blanchette J, Rizzo K, Kohn E.
CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70.
Oncogene. 19: 4385-95, 2000. [Journal]
143)  Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK.
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Microvasc. Res. 60: 70-80, 2000. [Journal]
144)  Hodgson L, Kohn EC, Dong C.
Extracellular lipid-mediated signaling in tumor-cell activation and pseudopod protrusion.
Int J Cancer. 88: 593-600, 2000. [Journal]
145)  Brown MR, Kohn EC, Hutter RV.
The new millennium: applying novel technology to the study of the cancer cell in situ.
Cancer. 88: 2-5, 2000. [Journal]
146)  Brown MR, Kohn EC, Hutter RV.
The new millennium: applying novel technology to the study of the cancer cell in situ.
Eur J Nucl Med. 27: S27-30, 2000. [Journal]
147)  Brown MR, Chuaqui R, Vocke CD, Berchuck A, Middleton LP, Emmert-Buck MR, Kohn EC.
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Gynecol. Oncol. 74: 98-102, 1999. [Journal]
148)  Masiero L, Lapidos KA, Ambudkar I, Kohn EC.
Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: role of calcium influx.
J. Cell. Sci. 112 ( Pt 19): 3205-13, 1999. [Journal]
149)  Sandor V, Reed E, Sarosy G, Middleton LP, Davis P, Kohn E.
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival.
Ann. Oncol. 10: 585-8, 1999. [Journal]
150)  Peterson LA, Brown MR, Carlisle AJ, Kohn EC, Liotta LA, Emmert-Buck MR, Krizman DB.
An improved method for construction of directionally cloned cDNA libraries from microdissected cells.
Cancer Res. 58: 5326-8, 1998. [Journal]
151)  Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC.
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Cancer. 83: 1980-8, 1998. [Journal]
152)  Kohn EC.
Endostatin and angiostatin: the next anti-angiogenesis generation.
Angiogenesis. 2: 25-7, 1998. [Journal]
153)  Alessandro R, Masiero L, Lapidos K, Spoonster J, Kohn EC.
Endothelial cell spreading on type IV collagen and spreading-induced FAK phosphorylation is regulated by Ca2+ influx.
Biochem. Biophys. Res. Commun. 248: 635-40, 1998. [Journal]
154)  Luzzi KJ, Varghese HJ, MacDonald IC, Schmidt EE, Kohn EC, Morris VL, Marshall KE, Chambers AF, Groom AC.
Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI).
Angiogenesis. 2: 373-9, 1998. [Journal]
155)  Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, Figg WD.
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Journal of pharmacokinetics and biopharmaceutics. 26: 673-87, 1998. [Journal]
156)  Kohn EC.
Angiogenesis in ovarian carcinoma: a formidable biomarker.
Cancer. 80: 2219-21, 1997. [Journal]
157)  Lambert PA, Somers KD, Kohn EC, Perry RR.
Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines.
Surgery. 122: 372-8; discussion 378-9, 1997. [Journal]
158)  Wu Y, Palad AJ, Wasilenko WJ, Blackmore PF, Pincus WA, Schechter GL, Spoonster JR, Kohn EC, Somers KD.
Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.
Clin. Cancer Res. 3: 1915-21, 1997. [Journal]
159)  Jacobs W, Mikkelsen T, Smith R, Nelson K, Rosenblum ML, Kohn EC.
Inhibitory effects of CAI in glioblastoma growth and invasion.
J. Neurooncol. 32: 93-101, 1997. [Journal]
160)  Masiero L, Figg WD, Kohn EC.
New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12.
Angiogenesis. 1: 23-35, 1997. [Journal]
161)  Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E.
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Biopharm Drug Dispos. 18: 347-59, 1997. [Journal]
162)  Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E.
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
J. Clin. Oncol. 15: 1985-93, 1997. [Journal]
163)  Spoonster JR, Masiero L, Savage SA, Probst J, Kohn EC.
Regulation of cell spreading during differentiation in the muscarinic M5 receptor tumor-suppressor model.
Int. J. Cancer. 72: 362-8, 1997. [Journal]
164)  Alessandro R, Pugnaloni A, Biagini G, Kohn EC.
Regulation of cellular tyrosine phosphorylation by stimulatory and inhibitory muscarinic acetylcholine receptors.
Exp. Cell Res. 234: 18-26, 1997. [Journal]
165)  Yasui H, Butscher W, Cohen M, Spriggs N, Wersto R, Kohn EC, Liotta L, Gardner K.
Selective inhibition of mitogen-induced transactivation of the HIV long terminal repeat by carboxyamidotriazole. Calcium influx blockade represses HIV-1 transcriptional activation.
J. Biol. Chem. 272: 28762-70, 1997. [Journal]
166)  Rodland KD, Wersto RP, Hobson S, Kohn EC.
Thapsigargin-induced gene expression in nonexcitable cells is dependent on calcium influx.
Mol. Endocrinol. 11: 281-91, 1997. [Journal]
167)  Price JT, Bonovich MT, Kohn EC.
The biochemistry of cancer dissemination.
Crit. Rev. Biochem. Mol. Biol. 32: 175-253, 1997. [Journal]
168)  Reed E, Sarosy G, Kohn E, Christian M, Link CJ, Goldspiel B, Davis P, Jacob J, Maher M.
A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.
Gynecol. Oncol. 61: 349-53, 1996. [Journal]
169)  Kohn EC, Sarosy GA, Davis P, Christian M, Link CE, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A, Reed E.
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Gynecol. Oncol. 62: 181-91, 1996. [Journal]
170)  Link CJ, Reed E, Sarosy G, Kohn EC.
Borderline ovarian tumors.
Am. J. Med. 101: 217-25, 1996. [Journal]
171)  Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA.
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Cancer Res. 56: 569-73, 1996. [Journal]
172)  Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL, Schellhammer PF.
Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines.
Int. J. Cancer. 68: 259-64, 1996. [Journal]
173)  Sandor V, Hassan R, Kohn E.
Exacerbation of pseudogout by granulocyte colony-stimulating factor.
Ann. Intern. Med. 125: 781, 1996. [Journal]
174)  Soltis MJ, Yeh HJ, Cole KA, Whittaker N, Wersto RP, Kohn EC.
Identification and characterization of human metabolites of CAI [5-amino-1-1(4'-chlorobenzoyl-3,5-dichlorobenzyl)-1,2,3-triazole- 4-carboxamide).
Drug Metab. Dispos. 24: 799-806, 1996. [Journal]
175)  Kohn EC, Alessandro R, Probst J, Jacobs W, Brilley E, Felder CC.
Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2.
J. Biol. Chem. 271: 17476-84, 1996. [Journal]
176)  Reed E, Bitton R, Sarosy G, Kohn E.
Paclitaxel dose intensity.
J Infus Chemother. 6: 59-63, 1996. [Journal]
177)  Alessandro R, Spoonster J, Wersto RP, Kohn EC.
Signal transduction as a therapeutic target.
Curr. Top. Microbiol. Immunol. 213 ( Pt 3): 167-88, 1996. [Journal]
178)  Link CJ, Kohn E, Reed E.
The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects.
Gynecol. Oncol. 60: 347-54, 1996. [Journal]
179)  Alessandro R, Masiero L, Liotta LA, Kohn EC.
The role of calcium in the regulation of invasion and angiogenesis.
In Vivo. 10: 153-60, 1996. [Journal]
180)  Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA.
Angiogenesis: role of calcium-mediated signal transduction.
Proc. Natl. Acad. Sci. U.S.A. 92: 1307-11, 1995. [Journal]
181)  Link CJ, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E.
Cutaneous manifestations of Taxol therapy.
Invest New Drugs. 13: 261-3, 1995. [Journal]
182)  Volpe DA, Cole K, Sandeen MA, Kohn EC.
In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells.
Am. J. Hematol. 50: 277-82, 1995. [Journal]
183)  Alessandro R, Kohn EC.
Molecular genetics of cancer. Tumor invasion and angiogenesis.
Cancer. 76: 1874-7, 1995. [Journal]
184)  Kohn EC, Liotta LA.
Molecular insights into cancer invasion: strategies for prevention and intervention.
Cancer Res. 55: 1856-62, 1995. [Journal]
185)  Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M.
Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.
Semin. Oncol. 22: 90-6, 1995. [Journal]
186)  .
Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo.
Clin. Cancer Res. 1: 399-405, 1995. [Journal]
187)  Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ.
Tumor angiogenesis in advanced stage ovarian carcinoma.
Am. J. Pathol. 147: 33-41, 1995. [Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/12/2013.